NEW YORK (GenomeWeb News) – Qiagen announced today that it has acquired licenses from Roche and Idaho Technology related to instrumentation and reagents involved in PCR-based molecular testing.
Under the agreement, Qiagen has rights to thermal cycler and real-time PCR methods involved in diagnostic and other applications as well as novel PCR technology called high resolution melting curve analysis (HRM).
The deal provides Qiagen with the opportunity to offer a complete range of HRM-related instruments and reagents around the world for any research or diagnostic purpose, making it the first Idaho Tech/Roche licensee to obtain such rights.
According to Qiagen, HRM is compatible with its Rotor-Gene Q detection platform and has applications for everything from mutations discovery and pathogen detection to methylation analysis.
Qiagen is currently releasing HRM products — such as a range of HRM PCR kits and software for HRM-based genotyping — that rely on the complete license portfolio as well as its own intellectual property. The company also plans to seek regulatory approval in the US and Europe for sample and assay technologies involving its Rotor-Gene Q platform.
"This additional IP portfolio enables us to develop and market PCR solutions based on of the most advanced technologies for molecular diagnostics," Achim Ribbe, Qiagen's executive director of business development, said in a statement. "We now have a PCR intellectual property estate that we believe is truly unique. It puts us in the position to offer our customers … the latest PCR technology running on the most versatile platform and covering all markets and fields, including human in vitro diagnostics."
Financial terms of the agreement were not disclosed.